New C. diff treatment reduces recurrent infections by 40 percent

(University of Leeds) Recurrences of C. diff are common after antibiotic treatment. Now a University of Leeds study has found that the addition of a human monocalonal antibody to standard antibiotic treatment can reduce the risk of a repeat infection by 37 percent. Bezlotoxumab works by neutralising a toxin produced by the C. diff bacteria that damages the gut wall.

from EurekAlert! - Social and Behavioral Science http://ift.tt/2jT6Red